Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Eli Lilly's tirzepatide (Mounjaro/Zepbound) has surpassed Merck's Keytruda to become the world's best-selling drug, generating $10.1 billion in Q3 sales compared to Keytruda's $8.1 billion, highlighting the rapid market dominance of GLP-1-based treatments. This swift ascent, just a year after obesity approval, underscores the intense competition in the obesity market, where Lilly is now perceived to lead in efficacy over Novo Nordisk. Concurrently, Lilly reported Q3 revenue of $17.6 billion, exceeding analyst estimates, and raised its full-year sales guidance to $63-$63.5 billion and adjusted EPS guidance to $23.00-$23.70, signaling robust financial performance and strong market positioning.

Analysis

Eli Lilly's tirzepatide (Mounjaro/Zepbound) has rapidly become the world's best-selling drug, generating $10.1 billion in Q3 sales, significantly surpassing Merck's Keytruda at $8.1 billion. This swift ascent is notable, given tirzepatide's recent approvals in 2022 for diabetes and last year for obesity, contrasting with Keytruda's nine-year journey to top sales.

The shift underscores immense demand for GLP-1-based treatments and intense market competition, with Lilly now perceived to lead Novo Nordisk in weight loss efficacy. Further evidence of market intensity is Novo Nordisk's recent takeover bid for Metsera, which had previously announced an acquisition deal with Pfizer.

Concurrently, Eli Lilly reported robust Q3 total revenue of $17.6 billion, exceeding analyst forecasts of $16.1 billion. The company further demonstrated strong performance by raising its full-year sales guidance to $63-$63.5 billion from $60-$62 billion, and adjusted EPS guidance to $23.00-$23.70 from $21.75-$23.00.

Key Decisions for Investors

• Investors should consider Eli Lilly's strengthened market position and robust financial outlook, driven by the rapid success of tirzepatide and upward revised guidance.
• Monitor the evolving competitive landscape in the GLP-1 market, particularly the strategic responses from competitors like Novo Nordisk and the potential impact on Merck's Keytruda.
• Evaluate the long-term sustainability of GLP-1 demand and Lilly's ability to maintain its perceived efficacy lead amidst ongoing M&A and product development in the obesity and diabetes sectors.